As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the senior health, home health & hospice industry, including Chemed (NYSE:CHE) and its peers.

The senior health, home care, and hospice care industries provide essential services to aging populations and patients with chronic or terminal conditions. These companies benefit from stable, recurring revenue driven by relationships with patients and families that can extend many months or even years. However, the labor-intensive nature of the business makes it vulnerable to rising labor costs and staffing shortages, while profitability is constrained by reimbursement rates from Medicare, Medicaid, and private insurers. Looking ahead, the industry is positioned for tailwinds from an aging population, increasing chronic disease prevalence, and a growing preference for personalized in-home care. Advancements in remote monitoring and telehealth are expected to enhance efficiency and care delivery. However, headwinds such as labor shortages, wage inflation, and regulatory uncertainty around reimbursement could pose challenges. Investments in digitization and technology-driven care will be critical for long-term success.

The 7 senior health, home health & hospice stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 2%.

In light of this news, share prices of the companies have held steady as they are up 1.8% on average since the latest earnings results.

Chemed (NYSE:CHE)

With a unique business model combining end-of-life care and household services, Chemed (NYSE:CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services.

Chemed reported revenues of $640 million, up 9.2% year on year. This print exceeded analysts’ expectations by 0.6%. Overall, it was a satisfactory quarter for the company with a narrow beat of analysts’ full-year EPS guidance estimates.Chemed Total Revenue

The stock is up 10.6% since reporting and currently trades at $605.

Is now the time to buy Chemed? Access our full analysis of the earnings results here, it’s free.

Best Q4: Option Care Health (NASDAQ:OPCH)

With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ:OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States.

Option Care Health reported revenues of $1.35 billion, up 19.7% year on year, outperforming analysts’ expectations by 4.9%. The business had an exceptional quarter with an impressive beat of analysts’ full-year EPS guidance estimates and a solid beat of analysts’ EPS estimates.

Story Continues

Option Care Health Total Revenue

Option Care Health pulled off the biggest analyst estimates beat and highest full-year guidance raise among its peers. The market seems content with the results as the stock is up 2.3% since reporting. It currently trades at $33.39.

Is now the time to buy Option Care Health? Access our full analysis of the earnings results here, it’s free.

Slowest Q4: Brookdale (NYSE:BKD)

With a network of over 650 communities serving approximately 59,000 residents across 41 states, Brookdale Senior Living (NYSE:BKD) operates senior living communities across the United States, offering independent living, assisted living, memory care, and continuing care retirement communities.

Brookdale reported revenues of $780.9 million, up 3.5% year on year, in line with analysts’ expectations. It was a slower quarter as it posted a significant miss of analysts’ EPS estimates.

Brookdale delivered the weakest performance against analyst estimates in the group. Interestingly, the stock is up 20.4% since the results and currently trades at $6.39.

Read our full analysis of Brookdale’s results here.

AdaptHealth (NASDAQ:AHCO)

With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ:AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.

AdaptHealth reported revenues of $856.6 million, flat year on year. This number surpassed analysts’ expectations by 3.3%. Overall, it was a strong quarter as it also recorded an impressive beat of analysts’ EPS estimates and full-year EBITDA guidance slightly topping analysts’ expectations.

AdaptHealth had the slowest revenue growth and weakest full-year guidance update among its peers. The stock is down 5.1% since reporting and currently trades at $8.11.

Read our full, actionable report on AdaptHealth here, it’s free.

Addus HomeCare (NASDAQ:ADUS)

Serving approximately 66,000 clients across 22 states with a focus on "dual eligible" Medicare and Medicaid beneficiaries, Addus HomeCare (NASDAQ:ADUS) provides in-home personal care, hospice, and home health services to elderly, chronically ill, and disabled individuals.

Addus HomeCare reported revenues of $297.1 million, up 7.5% year on year. This result beat analysts’ expectations by 2.7%. It was a very strong quarter as it also logged a solid beat of analysts’ sales volume estimates and a decent beat of analysts’ EPS estimates.

The stock is down 5.3% since reporting and currently trades at $102.97.

Read our full, actionable report on Addus HomeCare here, it’s free.

Market Update

In response to the Fed’s rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed’s 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump’s presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025.

Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

Join Paid Stock Investor Research

Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.

View Comments